We invest in curative therapies and technologies to transform groundbreaking research into viable companies.
Eos is unlocking the future of medicine.
Regenerative medicine is reshaping healthcare, moving beyond traditional treatments to target the root causes of disease. With advancements in cell, gene, and tissue therapies, the field presents an unprecedented opportunity to develop curative treatments rather than mere symptom management.
Eos BioInnovation stands at the forefront of this transformation, driven by a mission to turn cutting-edge science into real-world solutions. By partnering with world-class researchers and investors, Eos accelerates the journey from breakthrough discovery to life-changing therapies.
We empower investors and entrepreneurs by bridging the gap between research and market-ready solutions.
We have a diverse portfolio of modalities, technologies and disease indications across a select number of companies.
We add value at each step of our portfolio companies' development through direct strategic and operational involvement.
Eos has a strong history of nurturing startups that achieve significant milestones in a timely manner.
Our team, partners, affiliates, and advisors are individually successful as investors, scientists, and entrepreneurs.
By leveraging well-established contacts and relationships, Eos can be the first institutional investor in leading regenerative medicine projects and startups.
Eos’ powerful network within the life sciences community enables early involvement in high-potential regenerative medicine startups.
Eos and Panacea Venture Partnership for Growth.
Eos has a strategic working relationship with Panacea Venture, a global life sciences focused venture capital firm backed by prominent investors, family offices, and institutions. Panacea’s founder has over three decades of biotech/healthcare investing experience at leading venture capital firms and serves as the Chair of Eos’ Board of Directors. Panacea has been instrumental in the founding of Eos and is fully committed to supporting Eos’ vision. Eos has leveraged and will continue to leverage the Panacea team and its collective experience, knowledge base, and skill sets. Panacea has established a strong and consistent track record of success, and we will continue to access its vast and diverse networks and resources to benefit Eos’ own portfolio of investments.
.avif)
Our team, partners, and advisors are individually successful as investors, scientists, and entrepreneurs.
Brock had a leadership role in formation of the regenerative medicine field as Executive Director of the Harvard Stem Cell Institute from 2006-2021. In that time period, the number of affiliated faculty grew to 375 and the number of related spin-off companies surpassed 40. Brock was also the CEO of IVIVA Medical, an HSCI faculty spin-off, from 2018 to 2021 leading to a successful acquisition. He currently represents Eos on the board of many of its portfolio companies.
.jpeg)
With nearly three decades of venture experience, Jimmy most recently helped lead the healthcare practice at WI Harper, a US-Greater China venture fund, where he had been a Managing Director/Senior Partner since 2010. Prior to that, Jimmy was the Co-Founder and Managing Director/General Partner of tech focused funds AcerTechnology Ventures/iD Ventures. Jimmy has been a board member and advisor to technology and healthcare companies through their eventual sale or initial public offerings and advises several university and foundation-backed funds.
James is the Founder and Managing Partner of Panacea Venture, a life science focused fund he started in 2017, after managing partner roles at Vivo Ventures and Kleiner Perkins (KPCB) China. To date, Panacea has raised three USD funds and invested in over 30 private and public companies. James is a director on a number of publicly-listed healthcare companies and is board chair of several of Panacea's portfolio companies.
Eos Investment Professionals and Venture Fellows
Eos’ core team currently includes a full-time junior investment professional and several venture fellows. The fellows are PhD candidates or post-doctoral students in leading academic labs who work with us to primarily conduct due diligence and provide portfolio company support. We also work with a number of seasoned biotech professionals who assist with deal identification and diligence, as well as company formation and management support. We are further supported by and work closely with members of Panacea Venture’s team and interact with them practically on a daily basis.